RT Journal Article
SR Electronic
T1 Stimulation of vascular organoids with SARS-CoV-2 antigens increases endothelial permeability and regulates vasculopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.25.21255890
DO 10.1101/2021.04.25.21255890
A1 Khan, Abdullah O.
A1 Reyat, Jasmeet S.
A1 Bourne, Joshua H.
A1 Colicchia, Martina
A1 Newby, Maddy L.
A1 Allen, Joel D.
A1 Crispin, Max
A1 Youd, Esther
A1 Murray, Paul G.
A1 Taylor, Graham
A1 Stamataki, Zania
A1 Richter, Alex G.
A1 Cunningham, Adam F.
A1 Pugh, Matthew
A1 Rayes, Julie
YR 2021
UL http://medrxiv.org/content/early/2021/04/27/2021.04.25.21255890.abstract
AB Objective Thrombotic complications and vasculopathy have been extensively associated with severe COVID-19 infection, however the mechanisms by which endotheliitis is induced remain poorly understood. Here we investigate vascular permeability in the context of SARS-CoV-2-mediated endotheliitis in patient samples and a vascular organoid model.Methods and Results We report the presence of the Spike glycoprotein in pericytes associated with pericyte activation and increased endothelial permeability in post-mortem COVID-19 lung autopsies. A pronounced decrease in the expression of the adhesion molecule VE-cadherin is observed in patients with thrombotic complications. Interestingly, fibrin-rich thrombi did not contain platelets, did not colocalize with tissue factor and have heterogenous levels of Von Willebrand factor, suggesting a biomarker-guided therapy might be required to target thrombosis in severe patients. Using a 3D vascular organoid model, we observe that ACE2 is primarily expressed in pericytes adjacent to vascular networks, consistent with patient data, indicating a preferential uptake of the S glycoprotein by these cells. Exposure of vascular organoids to SARS-CoV-2 or its antigens, recombinant trimeric Spike glycoprotein and Nucleocapsid protein, reduced endothelial cell and pericyte viability as well as CD144 expression with no additive effect upon endothelial activation via IL-1β.Conclusions Our data suggest that pericyte uptake of SARS-CoV-2 or Spike glycoprotein contributes to vasculopathy by altering endothelial permeability increasing the risk of thrombotic complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAOK is a Henry Wellcome fellow (218649/Z/19/Z). JR is a British Heart Foundation Intermediate Fellow (FS/IBSRF/20/25039). This research was supported by BHF Accelerator Awards to JR and AOK (AA/18/2/34218). This research was funded, in whole or in part, by the Wellcome Trust (218649/Z/19/Z), British Heart Foundation (AA/18/2/34218) and COMPARE. A CC BY or equivalent licence is applied to AAM arising from this submission, in accordance with the grants open access conditions. M.C. was supported by the National Institute for Allergy and Infectious Diseases through the Scripps Consortium for HIV Vaccine Development (CHAVD) (AI144462), the University of Southampton Coronavirus Response Fund. M.C. was also supported by the International AIDS Vaccine Initiative (IAVI) through grant INV-008352/ OPP1153692 and the IAVI Neutralizing Antibody Center through the Collaboration for AIDS Vaccine Discovery grant INV-008813/OPP1196345, both funded by the Bill and Melinda Gates Foundation. No payment or services were received from a third party.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics for patient tissue sections were approved by the Health Research Authority (HRA) with an NHS (National Health Service) REC (Research Ethics Committee) approval issued by North East- Newcastle and North Tyneside 1 (19/NE/0336). Ethical approval was granted.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact corresponding authors re any data requests.